All PlansCoverageMedium impact
Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Ovarian Cancer (BRCA1, BRCA2, Homologous Recombination Deficiency, NTRK)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, OB-GYN·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a new comprehensive medical policy covering germline and somatic biomarker testing (including liquid biopsy) for targeted treatment in ovarian cancer, focusing on BRCA1, BRCA2, homologous recombination deficiency, and NTRK testing. The policy establishes coverage criteria and companion diagnostic requirements for various FDA-approved targeted therapies including PARP inhibitors and NTRK fusion inhibitors.
Action Required
Immediately: Review this new policy with oncology and gynecology providers to understand coverage criteria for ovarian cancer biomarker testing. Update prior authorization workflows to ensure compliance with companion diagnostic requirements for targeted therapies like Lynparza, Zejula, and Rubraca. Train billing staff on the specific biomarker testing requirements and approved companion diagnostics listed in the policy.